Melanoma resistance to photodynamic therapy: new insights
Melanoma is the most dangerous form of skin cancer, with a steeply rising incidence and a poor prognosis in its advanced stages. Melanoma is highly resistant to traditional chemotherapy and radiotherapy, although modern targeted therapies such as BRAF inhibitors are showing some promise. Photodynami...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Walter de Gruyter
2016
|
| Online Access: | http://hdl.handle.net/1721.1/103056 |
| _version_ | 1826210653533110272 |
|---|---|
| author | Huang, Ying-Ying Vecchio, Daniela Avci, Pinar Yin, Rui Garcia-Diaz, Maria Hamblin, Michael R. |
| author2 | Institute for Medical Engineering and Science |
| author_facet | Institute for Medical Engineering and Science Huang, Ying-Ying Vecchio, Daniela Avci, Pinar Yin, Rui Garcia-Diaz, Maria Hamblin, Michael R. |
| author_sort | Huang, Ying-Ying |
| collection | MIT |
| description | Melanoma is the most dangerous form of skin cancer, with a steeply rising incidence and a poor prognosis in its advanced stages. Melanoma is highly resistant to traditional chemotherapy and radiotherapy, although modern targeted therapies such as BRAF inhibitors are showing some promise. Photodynamic therapy (PDT, the combination of photosensitizing dyes and visible light) has been tested in the treatment of melanoma with some promising results, but melanoma is generally considered to be resistant to it. Optical interference by the highly-pigmented melanin, the antioxidant effect of melanin, the sequestration of photosensitizers inside melanosomes, defects in apoptotic pathways, and the efflux of photosensitizers by ATP-binding cassette transporters have all been implicated in melanoma resistance to PDT. Approaches to overcoming melanoma resistance to PDT include: the discovery of highly active photosensitizers absorbing in the 700–800-nm near infrared spectral region; interventions that can temporarily reduce the amount or pigmentation of the melanin; compounds that can reverse apoptotic defects or inhibit drug-efflux of photosensitizers; and immunotherapy approaches that can take advantage of the ability of PDT to activate the host immune system against the tumor being treated. |
| first_indexed | 2024-09-23T14:53:22Z |
| format | Article |
| id | mit-1721.1/103056 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T14:53:22Z |
| publishDate | 2016 |
| publisher | Walter de Gruyter |
| record_format | dspace |
| spelling | mit-1721.1/1030562022-10-01T23:12:21Z Melanoma resistance to photodynamic therapy: new insights Huang, Ying-Ying Vecchio, Daniela Avci, Pinar Yin, Rui Garcia-Diaz, Maria Hamblin, Michael R. Institute for Medical Engineering and Science Harvard University--MIT Division of Health Sciences and Technology Hamblin, Michael R. Melanoma is the most dangerous form of skin cancer, with a steeply rising incidence and a poor prognosis in its advanced stages. Melanoma is highly resistant to traditional chemotherapy and radiotherapy, although modern targeted therapies such as BRAF inhibitors are showing some promise. Photodynamic therapy (PDT, the combination of photosensitizing dyes and visible light) has been tested in the treatment of melanoma with some promising results, but melanoma is generally considered to be resistant to it. Optical interference by the highly-pigmented melanin, the antioxidant effect of melanin, the sequestration of photosensitizers inside melanosomes, defects in apoptotic pathways, and the efflux of photosensitizers by ATP-binding cassette transporters have all been implicated in melanoma resistance to PDT. Approaches to overcoming melanoma resistance to PDT include: the discovery of highly active photosensitizers absorbing in the 700–800-nm near infrared spectral region; interventions that can temporarily reduce the amount or pigmentation of the melanin; compounds that can reverse apoptotic defects or inhibit drug-efflux of photosensitizers; and immunotherapy approaches that can take advantage of the ability of PDT to activate the host immune system against the tumor being treated. National Institutes of Health (U.S.) (NIH grant (R01AI050875)) Fondazione Monte dei Paschi di Siena National Natural Science Foundation (China) (Grant No: 81172495)) Universitats i Empresa de la Generalitat de Catalunya i del Fons Social Europeu (Predoctoral fellowship) 2016-06-08T15:24:39Z 2016-06-08T15:24:39Z 2013-02 2012-08 Article http://purl.org/eprint/type/JournalArticle 1437-4315 1431-6730 http://hdl.handle.net/1721.1/103056 Huang, Ying-Ying, Daniela Vecchio, Pinar Avci, Rui Yin, Maria Garcia-Diaz, and Michael R. Hamblin. “Melanoma Resistance to Photodynamic Therapy: New Insights.” Biological Chemistry 394, no. 2 (January 1, 2013). en_US http://dx.doi.org/10.1515/hsz-2012-0228 Biological Chemistry Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf Walter de Gruyter Walter de Gruyter |
| spellingShingle | Huang, Ying-Ying Vecchio, Daniela Avci, Pinar Yin, Rui Garcia-Diaz, Maria Hamblin, Michael R. Melanoma resistance to photodynamic therapy: new insights |
| title | Melanoma resistance to photodynamic therapy: new insights |
| title_full | Melanoma resistance to photodynamic therapy: new insights |
| title_fullStr | Melanoma resistance to photodynamic therapy: new insights |
| title_full_unstemmed | Melanoma resistance to photodynamic therapy: new insights |
| title_short | Melanoma resistance to photodynamic therapy: new insights |
| title_sort | melanoma resistance to photodynamic therapy new insights |
| url | http://hdl.handle.net/1721.1/103056 |
| work_keys_str_mv | AT huangyingying melanomaresistancetophotodynamictherapynewinsights AT vecchiodaniela melanomaresistancetophotodynamictherapynewinsights AT avcipinar melanomaresistancetophotodynamictherapynewinsights AT yinrui melanomaresistancetophotodynamictherapynewinsights AT garciadiazmaria melanomaresistancetophotodynamictherapynewinsights AT hamblinmichaelr melanomaresistancetophotodynamictherapynewinsights |